Regulus Therapeutics Inc. - Common Stock (RGLS)
Frequently Asked Questions About Regulus Therapeutics Inc. - Common Stock (RGLS)
Are there any recent developments or announcements by Regulus?
Regulus Therapeutics regularly provides updates on its clinical trials, partnerships, and research progress. Checking their official website or press releases will reveal the latest developments, including advancements in their pipeline and financial updates.
Has Regulus Therapeutics faced any regulatory hurdles?
Yes, Regulus Therapeutics has encountered regulatory hurdles, like many biopharmaceutical companies, as navigating the clinical trial process, obtaining FDA approvals, and ensuring safety and efficacy of their drug candidates is a complex and demanding journey.
How does Regulus Therapeutics fund its research?
Regulus Therapeutics funds its research and development efforts through a combination of public and private investments, partnerships, grants, and strategic collaborations with other companies and institutions to ensure continued growth and innovation.
How does Regulus Therapeutics view its competitive position in the market?
Regulus Therapeutics views its competitive position as strong due to its unique focus on miRNA therapeutics, innovative research capabilities, and a commitment to developing first-in-class products that address significant health challenges in the biopharmaceutical landscape.
Is Regulus Therapeutics publicly traded?
Yes, Regulus Therapeutics Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol 'RGLS,' allowing investors to buy and sell shares of the company.
What are some key products in Regulus's pipeline?
Regulus Therapeutics has several promising candidates in its pipeline, including RG-101 and RG-012, which target specific miRNAs involved in hepatitis C and kidney disease, respectively, and are designed to provide therapeutic benefits by restoring normal gene expression.
What does Regulus Therapeutics Inc. do?
Regulus Therapeutics Inc. is a biopharmaceutical company that focuses on discovering and developing innovative medicines based on the modulation of microRNAs (miRNAs), which are small molecules that play critical roles in the regulation of gene expression and various cellular processes.
What financial challenges has Regulus Therapeutics faced?
Like many biopharmaceutical companies, Regulus Therapeutics has faced financial challenges including the need for significant funding for research and development, market competition, and regulatory hurdles that can impact its ability to bring products to market.
What is Regulus Therapeutics's mission?
Regulus Therapeutics's mission is to unlock the potential of microRNAs to create transformative treatments for patients suffering from serious diseases, ultimately improving health outcomes through innovative biopharmaceutical solutions.
What is RG-012?
RG-012 is an investigational drug candidate designed to treat Alport syndrome by targeting microRNA-21. It aims to restore proper function in kidney cells affected by the condition, potentially preserving kidney function in patients.
What is RG-101?
RG-101 is an RNA-targeted therapeutic product candidate developed by Regulus to treat hepatitis C virus (HCV) infections. It works by targeting microRNA-122, which the virus relies on for replication, aiming to disrupt the virus's life cycle.
What is the focus of Regulus's research?
Regulus's research is primarily focused on microRNA (miRNA) therapeutics, with the goal of unlocking the potential of these small RNA molecules in addressing various diseases, including cancer, liver disease, and other conditions where miRNA dysregulation occurs.
What is the significance of microRNAs in Regulus's research?
MicroRNAs are essential regulatory molecules that influence gene expression. Their dysregulation can lead to diseases, making them valuable targets for innovative therapeutics. Regulus's research harnesses the unique properties of miRNAs to develop potential drugs that can correct these imbalances.
What is the target market for Regulus Therapeutics's products?
Regulus Therapeutics aims to target several significant markets within the biopharmaceutical industry, focusing initially on diseases with unmet medical needs, such as viral infections and genetic disorders, where innovative miRNA therapies could offer substantial clinical benefits.
What partnerships does Regulus Therapeutics have?
Regulus Therapeutics has engaged in strategic collaborations with various pharmaceutical companies and academic institutions to further its research and development efforts. These collaborations aim to leverage combined expertise and resources to accelerate the progression of its therapeutic candidates.
When was Regulus Therapeutics Inc. founded?
Regulus Therapeutics Inc. was founded in 2007, emerging from a collaboration between the San Diego-based Biogen Idec and the renowned academic institutions of Harvard University and the Scripps Research Institute.
Where is Regulus Therapeutics Inc. headquartered?
Regulus Therapeutics Inc. is headquartered in San Diego, California, a hub for biotechnology and life sciences, providing the company access to top talent and innovative research environments.
Who are the key members of Regulus Therapeutics's management team?
Regulus Therapeutics's management team consists of experienced professionals from the biopharmaceutical industry and academia, bringing extensive expertise in drug development, regulatory affairs, and corporate leadership to guide the company's strategic direction.
What is the current price of Regulus Therapeutics Inc. - Common Stock?
The current price of Regulus Therapeutics Inc. - Common Stock is 1.645
When was Regulus Therapeutics Inc. - Common Stock last traded?
The last trade of Regulus Therapeutics Inc. - Common Stock was at 3:47 pm EDT on April 7th, 2025
What is the market capitalization of Regulus Therapeutics Inc. - Common Stock?
The market capitalization of Regulus Therapeutics Inc. - Common Stock is 143.18M
How many shares of Regulus Therapeutics Inc. - Common Stock are outstanding?
Regulus Therapeutics Inc. - Common Stock has 87.04M shares outstanding.